Applies to vecuronium: parenteral powder for injection.
Warning
Special Alerts:
A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].
Side effects include:
Skeletal muscle weakness.
For Healthcare Professionals
Applies to vecuronium: intravenous powder for injection, intravenous solution.
Hypersensitivity
Very rare (less than 0.01%): Hypersensitivity, anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, anaphylactoid shock[Ref]
Musculoskeletal
Rare (0.01% to 0.1%): Prolonged neuromuscular block
Very rare (less than 0.01%): Flaccid paralysis, muscular weakness, steroid myopathy[Ref]
Respiratory
Very rare (less than 0.01%): Bronchospasm, airway complication of anesthesia[Ref]
Local
Very rare (less than 0.01%): Injection site pain, injection site reaction[Ref]
Other
Rare (0.01% to 0.1%): Decreased drug effect/therapeutic response, increased drug effect/therapeutic response
Very rare (less than 0.01%): Face edema[Ref]
Nervous system
Rare (less than 0.1%): Delayed recovery from anesthesia[Ref]
Cardiovascular
Rare (0.01% to 0.1%): Tachycardia, hypotension
Very rare (less than 0.01%): Circulatory collapse, shock, flushing[Ref]
Dermatologic
Very rare (less than 0.01%): Angioneurotic edema, urticaria, rash, erythematous rash[Ref]
